GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avecho Biotechnology Ltd (ASX:AVE) » Definitions » Cash Ratio

Avecho Biotechnology (ASX:AVE) Cash Ratio : 6.53 (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Avecho Biotechnology Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Avecho Biotechnology's Cash Ratio for the quarter that ended in Dec. 2023 was 6.53.

Avecho Biotechnology has a Cash Ratio of 6.53. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Avecho Biotechnology's Cash Ratio or its related term are showing as below:

ASX:AVE' s Cash Ratio Range Over the Past 10 Years
Min: 1.69   Med: 4.18   Max: 11.63
Current: 6.53

During the past 13 years, Avecho Biotechnology's highest Cash Ratio was 11.63. The lowest was 1.69. And the median was 4.18.

ASX:AVE's Cash Ratio is ranked better than
73.23% of 1524 companies
in the Biotechnology industry
Industry Median: 2.9 vs ASX:AVE: 6.53

Avecho Biotechnology Cash Ratio Historical Data

The historical data trend for Avecho Biotechnology's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avecho Biotechnology Cash Ratio Chart

Avecho Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.89 3.10 4.69 1.97 6.53

Avecho Biotechnology Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.69 5.25 1.97 1.80 6.53

Competitive Comparison of Avecho Biotechnology's Cash Ratio

For the Biotechnology subindustry, Avecho Biotechnology's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avecho Biotechnology's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avecho Biotechnology's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Avecho Biotechnology's Cash Ratio falls into.



Avecho Biotechnology Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Avecho Biotechnology's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=5.504/0.843
=6.53

Avecho Biotechnology's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=5.504/0.843
=6.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avecho Biotechnology  (ASX:AVE) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Avecho Biotechnology Cash Ratio Related Terms

Thank you for viewing the detailed overview of Avecho Biotechnology's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Avecho Biotechnology (ASX:AVE) Business Description

Traded in Other Exchanges
Address
Unit A8, 2A Westall Road, Clayton, Melbourne, VIC, AUS, 3168
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sale, and licensing of products incorporating its patented platform technology TPM, for the pharmaceutical, skincare and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.

Avecho Biotechnology (ASX:AVE) Headlines

No Headlines